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Because the highest rates of morbidity and mortality in
neonates are seen in those born ato32 weeks’ gestation,
this group has the most urgent need for novel therapies to
improve survival and outcome. Legislative efforts in the
United States and Europe have attempted to address this
issue by requiring the study of drugs, biological and
nutritional products, devices, and other therapies in this
population through a combination of high-quality regu-
latory and clinical trials, quality improvement initiatives,
and observational studies. Because there are relatively
small numbers of very preterm neonates born each year
in any 1 country or continent, and because a signiﬁcant
number of clinical trials are recruiting at any 1 time, a
neonate may meet enrollment criteria for41 clinical trial.
Neonatal units that have the infrastructure and resources
to engage in research frequently face the question of
whether it is permissible to enroll a neonate in 41 trial.
This article examines the pertinent scientiﬁc, ethical,
regulatory, and industry issues that should be taken into
account when considering enrolling neonates in multiple
clinical studies. (Clin Ther. 2017;39:1959–1969) & 2017
The Authors. Published by Elsevier HS Journals, Inc.
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Many common neonatal care practices and therapies
have never been rigorously evaluated with adequate
efﬁcacy and safety data to support formal regulatory
approval. As a result, most treatments have evolved
into “best practice” and “standard of care” with
insufﬁcient evidence to support safety, efﬁcacy, dos-
age, and treatment exposure. The compelling need to
advance neonatal drug development has been recog-
nized and has resulted in US and European legislation
mandating more studies in this unique population. To
develop the tools, standards, and approaches needed
to accomplish this goal, the US Food and Drug
Administration (FDA) and the Critical Path Institute,
with support from the pharmaceutical industry, estab-
lished the International Neonatal Consortium. This
consortium brings together regulators, neonatologists,
nurses, pharmaceutical companies, funding organiza-
tions, and parent/community groups to advance1959
Clinical Therapeuticsregulatory science and address the needs of neo-
nates.1,2 However, neonates are seen as a highly
vulnerable population, with their participation in drug
development and clinical trials limited by numerous
factors.
Because the highest rates of morbidity and mortality
are seen in neonates born at o32 weeks’ gestation,
this group has the most urgent need for novel therapies
to improve survival and outcome. Because a small
fraction of live births occur at o32 weeks’ gestation
(1.5% in the United States),3 there are numerous
clinical trials recruiting at any 1 time and a relatively
small population of premature or ill neonates available
for enrollment. A country-wide sampling of the annual
number of preterm neonates born before 32 weeks’
gestation revealed ~3500 in Canada in 2012,4 8300 in
England and Wales in 2015,5 7100 in Japan in 2015,6
and 63,000 in the United States in 2015.3 The
expertise and resources needed to conduct these
studies tend to be concentrated in a limited number
of neonatal intensive care units, where most neonates
may be eligible to participate in 41 clinical trial at a
time.7 To continue to successfully improve neonatal
survival and outcome, we must study drugs, biological
and nutritional products, devices, and other therapies
in parallel through a combination of high-quality
clinical trials, quality improvement initiatives, and
noninterventional studies. With the constraints of the
small population of eligible neonates, progress will be
limited unless alternatives to restricting enrollment to
a single clinical trial are considered, including
developing new methods and study designs. The
present article examines the pertinent issues that
should be considered when enrolling neonates in
multiple studies.SCIENTIFIC CONSIDERATIONS WHEN
ENROLLING A NEONATE IN 41 CLINICAL
TRIAL
An initial approach is to consider the goal of clinical
research, which is to gather reliable information about
the balance between safety and efﬁcacy for each
product or intervention under investigation. Although
each trial seeks to standardize research-related varia-
bles, there is the additional challenge of practice
variability that occurs within and among neonatal
intensive care units. Although this “background
noise” may preclude detection of an effect of the1960intervention being tested, allowing practice variations
may better simulate how the intervention performs
under real-world conditions. When deciding whether
to allow enrollment of neonates in 41 study, the
impact of practice variability on interpretation of
study results should be considered.
How will enrollment of neonates in 41 trial affect
the validity of each individual trial? Each trial
describes clinical events with some level of accuracy,
attributes clinical events to 1 or more products or
interventions, and assigns a degree of reliability to the
description and attributions. These characteristics lead
to hazards that may arise in all trials, which can
include the following: (1) detection errors—the trial
may fail to describe an event because the event is too
rare, the event is not detected due to investigator
error, or there is a failure in data collection; (2)
misattribution—the trial may falsely attribute an event
to the intervention or may fail to attribute an event to
the trial; and (3) uncertainty—the information may
not be precise enough for its intended use.
The extent to which these hazards may occur is
variable and can lead to consequences of misattribution
or uncertainty, such as: (1) reducing the precision of
estimates of safety or efﬁcacy, including altered effect
size if the interventions have opposite effects or if the
interventions are synergistic; (2) misattributing events
that could contribute to assessments of safety or
efﬁcacy to 1 intervention or another (trial or nontrial
related); and (3) alterations in drug disposition related
to enzyme induction or drug effects (eg, competitive
antagonism at a receptor that is the intended or an
unintended target) that will depend on the temporal
relationship between administration of the interven-
tions. During early-phase trials, proximate consequen-
ces could include imprecision in pharmacokinetic (PK)
or PK/pharmacodynamic (PD) relationships.
Drug–drug interactions are a major concern for
concurrent studies. Pharmacologic (eg, medications
for pain) or nonpharmacologic (eg, kangaroo care for
pain) interventions may ameliorate or exaggerate the
true effect of each intervention. The following types of
interactions are determinants of the intensity, quality,
or duration of drug response: (1) PK interactions in
which 1 drug inhibits or accelerates metabolism and
elimination of the other; (2) PD interactions in which
drugs may act at the receptor or effector level, masking
the true effect of the interventions; or (3) simple
chemical incompatibilities, which would negate theVolume 39 Number 10
J.M. Davis et al.effects of the drugs being given together. The need to
perform requisite evaluations of drugs for neonates
must address this conundrum with respect to drug
interactions.
Early-phase clinical trials require deﬁnition of true
pharmacologic effects on safety and potential efﬁcacy
in a small number of neonates. Simultaneous co-
enrollment should be avoided to generate accurate
PK data and evaluate PD variables with minimal
interactions, to allow proper design of advanced
protocols. In randomized trials, studying ≥2 drugs
or nonpharmacologic interventions with known inter-
actions of any type should be avoided. Convenience
sampling from neonates who receive multiple medi-
cations for clinical indications with known interac-
tions (eg, drugs for patent ductus arteriosus closure
and aminoglycosides) may be useful.STRATEGIES TO CONSIDER WHEN
PLANNING FOR CO-ENROLLMENT
Although enrollment in41 clinical trial can be highly
problematic, there are other instances in which it may
be permissible (Table I). For example, enrollment in
41 simultaneous or sequential clinical trial should be
avoided if the primary end points of the 2 trials are
similar, as attribution of main effects to 1 or the other
trial would be extremely difﬁcult. The exception
would be if the trials were combined in a factorial
design, in which participants are randomized to 1 or
more interventions from the outset (ie, 4 arms
including standard of care, intervention A,
intervention B, and interventions A þ B). The
impact of each arm’s treatment on the primary end
point can then be evaluated. However, factorial trials
require a substantial increase in the sample size to
evaluate interactions between interventions.8–10Table I. Co-enrollment in clinical trials.
Avoid Co-enrollment
Early-phase PK studies B
Randomized trials studying ≥2 drugs or interventions
with known interactions
D
Trials with similar primary end points F
If each trial is speciﬁcally targeting the same organ
system
T
October 2017Enrollment in 41 trial should also generally be
avoided when each of the trials is evaluating a novel
therapy because the disposition of the new drugs may
not be well characterized, and robust safety or efﬁcacy
information may not be available. Drugs that are not
approved or marketed for a neonatal indication, but
have been widely studied and are considered current
standards of care, may not be subject to this restric-
tion if other criteria are met for safety evaluation and
scientiﬁc integrity.
There are several scenarios in which enrollment in
41 trial is unlikely to compromise safety or scientiﬁc
validity of either trial. Short PK and/or safety studies
or device validation studies separated by a scientiﬁ-
cally determined period of time from an interventional
study may be permissible. In the review by
Myles et al9 of ethical and scientiﬁc considerations
for concurrent enrollment, co-enrollment may be
permitted if the following 3 conditions are met: (1)
the likelihood of enrollment in study B has not been
inﬂuenced by treatment in study A; (2) if neither
treatment inﬂuences the natural course of disease of
the other condition being studied; and (3) if there is
unlikely to be a drug–drug interaction. The review
highlights consideration of the potential increased
burden of various study procedures as well as
sample size adjustments and potential selection biases.
If co-enrollment is considered, it will require explo-
ration of scientiﬁc details, including: (1) the temporal
relationship between the antecedents of the effects
(whether the causal pathways of the relevant events
overlap in time); (2) what is known about the treatment
(s); (3) the phase of development for each product; (4)
the temporal relationships between interventions in each
trial; (5) whether there are overlapping absorption,
distribution, metabolism, and excretion pathways; (6)
whether there are potentially overlapping toxicities; andCo-enrollment May be Permissible
rief pharmacokinetic and or safety/studies
evice validation studies
actorial study designs with adequate sample sizes
rials of drugs routinely used and considered standard
of care for neonates
1961
Clinical Therapeutics(7) whether enrollment in an additional study may be
treated as a covariate in the statistical analysis.
Comparative effectiveness trials, in which ≥2
accepted strategies or treatments are being evaluated,
may use the covariate strategy to enable co-enroll-
ment. Because the potential for co-enrollment is high
in neonatal studies, it should be considered during
protocol development. Absolute decisions about co-
enrollment should be avoided, and speciﬁc language
addressing when co-enrollment may or may not be
permissible should be included in protocols. Speciﬁc
limitations should be based on informed, well-rea-
soned judgment or statistical criteria. Other strategies
that may be considered when planning neonatal
studies in which the question of co-enrollment could
arise include: (1) accepting a low level of co-enroll-
ment when it is believed to be unlikely to lead to
serious consequences and may facilitate recruitment;
(2) adopting a conservative approach with no co-
enrollment allowed, which may lead to difﬁculty
ﬁnding an adequate number of study sites, increased
competition among studies, and ultimately slow re-
search progress; and (3) clinical trial simulation and
modeling to generate quantitative estimates of the
range and magnitude of the risks and/or interactions.
In summary, the scientiﬁc validity of a clinical trial
may be undermined by co-enrollment through a
potential effect on the statistical power of the individ-
ual trials and/or an interaction between the 2 inter-
ventions.7,9 An interaction may also lead to different
conclusions about safety and/or efﬁcacy of 1 or both
interventions that might not have been apparent in
separate clinical trials.9,10 In addition to concerns
about statistical power, increased risk of adverse
events (AEs), and the interpretation of study results,
there may be a problem with outcome ascertainment
bias.11 Thus, whether to allow co-enrollment in 41
clinical trial requires a careful assessment of the
potential impact on the study results, interactions
between the interventions, subject safety, and the
scientiﬁc validity of the clinical trials.12–15ETHICAL CONSIDERATIONS WHEN
ENROLLING A NEONATE IN 41 CLINICAL
TRIAL
The primary principle to consider as stated by the
International Conference on Harmonisation in its
Guideline for Good Clinical Practice (ICH-E6) is that1962the child’s interest should always prevail over that of
science and society. This principle is paramount when
assessing and monitoring risks. There are several
ethical issues that must be addressed if co-enrollment
in 41 clinical trial is to be allowed: (1) co-enrollment
may inadvertently increase the risks and burdens
beyond those that would otherwise have been allow-
able for each clinical trial considered alone, especially
for nonbeneﬁcial (eg, “research only”) procedures
such as blood draws; (2) the impact of either allowing
or disallowing co-enrollment in 41 clinical trial on
parental decision-making must be considered; and (3)
co-enrollment must not undermine the scientiﬁc
validity of either clinical trial.
Parental Permission
Not allowing parents to co-enroll their neonates in
studies that they would want to support and whose
risks and beneﬁts have been explained to them seems
to restrict their right to exercise such choices on behalf
of their neonate.9 Although it may be reasonable to
restrict co-enrollment if it would undermine the
scientiﬁc validity of the clinical trials, this approach
does not address the question of which clinical trial
should be offered to the parent(s). Allowing co-
enrollment, when scientiﬁcally appropriate, respects
the role of parents in deciding for their neonate and
may result in a more representative population of
those neonates who would receive the 2 interventions
in clinical practice.7,9,11 There are no data to indicate
that it may be too stressful and thus unethical to
approach parents about co-enrollment in multiple
studies.10 One study showed that most mothers of
neonates were willing to participate in 41 study.7 In
another study, most parents (74%) of preterm
neonates were comfortable with enrollment in 41
study at any one time with a minority (22%) being
worried about the number of studies.16 Co-enrollment
did not seem to have an impact on recruitment.13
When co-enrollment is an appropriate option
(whether at the same time or in sequence), parents
should be fully informed about the available studies,
including any potential interactions between the stud-
ies (eg, the chances of an unknown drug–drug inter-
action). Although it seems that parents are generally
supportive of co-enrollment, it is important to recog-
nize that having a critically ill neonate can be difﬁcult,
and parents should be supported throughout the
entire clinical trials process.16–18Volume 39 Number 10
J.M. Davis et al.Risks and Burdens of Participation
According to FDA regulations, a nonbeneﬁcial (or
"research only") procedure must present no more
than minimal risk (21 CFR 50.51) or no more than
a minor increase over minimal risk (21 CFR 50.53).
Outside of the United States, existing regulations and/
or guidance limit such procedures to no more than
minimal risk, yet neither deﬁne minimal risk nor
deﬁne it as comparable to the routine clinical experi-
ence of the enrolled research population.19 This
approach is the one taken by the addendum to the
ICH E-11 to harmonize the United States with other
approaches. Within the United States, minimal risk is
usually limited to routine physical and psychological
examinations of healthy children. The category of
minor increase over minimal risk is not deﬁned but is
limited to children with the disorder or condition
(suggesting that this level of risk is similar to the
routine clinical care of children enrolled in the
research, consistent with international guidance on
minimal risk). Perhaps for this reason, ICH E-6 uses
the term "low risk" to describe the appropriate risk
level for nonbeneﬁcial procedures performed on
individuals who are unable to consent for
themselves. An individual procedure may qualify as
either minimal risk or a minor increase over minimal
risk, but when performed multiple times over a limited
period of time, the overall risk may exceed an
acceptable threshold. Thus, co-enrollment may result
in a risk exposure that exceeds minimal risk/minor
increase over minimal risk. As such, a research ethics
committee should be aware of the possibility of co-
enrollment and approve this possibility in advance.
Observational studies may not involve a change in
clinical treatment, but additional blood draws and/or
monitoring could place an additional burden on a
neonate. Although that burden for an individual study
may be reasonable, the additive effects of multiple
studies may be unreasonable.7 Blood sampling for
both clinical care and research must be coordinated to
minimize discomfort and to keep the total volume of
blood drawn within acceptable limits.15REGULATORY CONSIDERATIONS WHEN
ENROLLING A NEONATE IN 41 CLINICAL
TRIAL
Regulatory agencies and the ICH have not issued
comprehensive guidance regarding co-enrollment.October 2017Adherence to the principles of sound trial design and
scientiﬁc validity is critical in the assessment of
whether co-enrollment may be considered. Regulatory
agencies, with their charge to protect the public
health, must thoroughly consider the potential safety
implications of any study design alongside its potential
to demonstrate efﬁcacy.
Although Health Canada does not have any regu-
lations speciﬁc to pediatrics in general or neonates in
particular, the conduct of clinical trials in children
from birth to 18 years of age can be requested as
necessary. Health Canada does have guidelines that
allow for ﬂexibility in regulatory decision-making, as
long as a suitable scientiﬁc and clinical rationale is
provided. This ﬂexibility could potentially allow en-
rollment of neonates in 41 trial when deemed scien-
tiﬁcally and ethically sound. Consideration should be
given to the duration and timing of each study together
with its measured outcomes, as well as the potential to
use nonstandard or adaptive designs and analyses.
A pediatric investigation plan and/or waiver cover-
ing the entire pediatric population, including neo-
nates, is mandatory for the authorization of a new
medicinal product in the European Union. These are
reviewed and agreed by the Paediatric Committee at
the European Medicines Agency (EMA) in the frame-
work of the Paediatric Regulation (Regulation [EC]
No. 1901/2006). In addition, EMA can provide advice
on clinical trial protocols through its Scientiﬁc Advice
Working Party. Whereas co-enrollment is not specif-
ically referred to and the considerations outlined in
this article with respect to scientiﬁc, safety, and ethical
considerations are valid, there are opportunities to
discuss such approaches at EMA through scientiﬁc
advice20 or during the pediatric investigation plan
procedure.21 The authorization of clinical trials occurs
at each member state level.22
Enrollment of neonates in 41 regulated clinical
trial or 1 regulated trial and a non-FDA regulated trial
has been permitted by the FDA in speciﬁc circum-
stances. The FDA Draft Guidance (“Informed Con-
sent Information Sheet: Guidance for IRBs, Clinical
Investigators, and Sponsors”) issued in 2014 referen-
ces participation in 41 clinical trial. The Draft
Guidance states,23 “FDA strongly discourages these
practices as enrollment in 41 clinical investigation
could increase risks to subjects, particularly because
they may be exposed to 41 investigational product
for which the safety proﬁle may not be well1963
Clinical Therapeuticsunderstood. Undoubtedly, enrollment of a single
patient in studies of two or more novel agents
would increase risk and potentially confound safety
and efﬁcacy assessments.”
Many neonatal therapies have been used off-label
for decades or longer. For those drugs, the safety
proﬁle may be reasonably well known. Clinical trials
using standard therapies may be acceptable alongside
a novel treatment trial as long as principles of
scientiﬁc validity are met (separate target organ
systems and/or primary end points). Regulatory agen-
cies are also invested in the principles of parental
permission and consent, and co-enrollment may be
accompanied by speciﬁc considerations in the permis-
sion process. Although regulatory agencies may differ
in approach to co-enrollment for neonatal trials, the
fundamental concerns are consistent: retaining the
scientiﬁc and statistical validity of individual studies,
maintaining the ability to detect signiﬁcant AEs,
ensuring parental permission is both informed and
voluntary, and, importantly, allowing access to inves-
tigational agents when there are no approved treat-
ments for a given condition.INDUSTRY CONSIDERATIONS WHEN
ENROLLING NEONATES IN 41 CLINICAL
TRIAL
Drug developers within pharmaceutical companies are
keenly aware of the challenges of recruiting and
performing neonatal clinical trials, especially with ex-
tremely preterm neonates. Enrollment can be exceed-
ingly slow, even when performing trials to prevent
bronchopulmonary dysplasia (BPD), 1 of the most
common diseases affecting preterm neonates. An anal-
ysis of recruitment rates in large studies evaluating BPD
prevention (as either a primary or secondary end point)
was recently performed by Chiesi Farmaceutici. A total
of 11 completed studies were identiﬁed, and the average
enrollment duration was nearly 4 years, with 1 trial
lasting47 years. The average recruitment rate was 1.3
neonates/site/month, with a range of 0.4 to 4 (Table II).
These prolonged periods of enrollment have
resulted in few drugs being adequately tested in
neonates. Therefore, industry investigators support
the concept of allowing participation in 41 study at
a time for neonates who: (1) are cared for at sites with
appropriate expertise; (2) have parents willing to have1964their neonate participate in research; and (3) meet
entry criteria. However, co-enrollment must be care-
fully evaluated with the support of scientiﬁc review
and regulatory guidance, to determine under which
conditions this co-enrollment would be permissible.
First, one must assess the type of studies to be
considered for co-enrollment. For example, studies
of a preventative therapy for BPD at the same time as
a preventative therapy for retinopathy of prematurity
would be difﬁcult to analyze, as these morbidities
are believed to have common etiologies. However, a
neonate who participated in an early prevention trial
may later be considered for eligibility in a treatment trial
for established complications of extreme prematurity.
Although many observational trials could be per-
formed within the same timeframe as the investiga-
tional drug trial, the drug may have an impact on the
results of the observational study. Nonpharmacologic
studies (eg, nutritional agents) may be viewed to have
small effects on drug study outcomes. However, poor
growth during the neonatal period can affect neonatal
morbidities as well as later neurodevelopmental out-
comes. Thus, the challenge of studying a new inves-
tigational drug and discerning which AE or serious
AEs can be ascribed to the new drug is challenging.
Comprehensive safety and AE data are not available
for the majority of neonatal therapies, and evaluating
AEs with 41 investigational drug can therefore be
difﬁcult. If the event is serious, the uncertainty of the
potential causative agent could place a promising
compound at risk, not only for neonatal use but for
even for older age groups.
Due to these concerns, many pharmaceutical com-
panies have adopted a policy in which neonates may
not be enrolled in a new trial until at least 30 days
after the end of active participation in a previous trial.
Operationally, there are also complications if the 2
studies are performed using agents developed by
separate companies for which different standard
operating procedures may exist and proprietary con-
cerns pose challenges to data sharing. Trial procedures
such as monitoring policies, consent processes, case
report forms, data entry, and AE reporting may
further complicate the studies and make them more
prone to errors. Under the right scientiﬁc and opera-
tional circumstances, concomitant studies should be
considered but only with very careful consideration of
the proposed concomitant trials.Volume 39 Number 10
Table II. Neonatal trials evaluating BPD prevention (primary or secondary outcome): sites, recruitment and target population.
Trial Title
Actual
Accrual
(Patients)
No. of
Sites
(Centers)
Trial
Start Date
Enrollment
Period Close
Date
Enrollment
Duration
(mo)
Recruitment
Rate
(Patients/
Site/Month) Indication Study Population
NIV Strategies for RDS in
preterm infants. NIV
(Noninvasive
Ventilation), RDS
(Respiratory Distress
Syndrome) (NIV)
280 2 1/1/2010 12/1/2012 35 4 RDS of
prematurity
VLBW infants
(birth weight
o1500 g and
GA o32 wk)
Can omega 3 fatty acids
improve respiratory
outcomes in preterm
infants. N3RO: (N-3
fatty acids for
improvement of
Respiratory Outcomes)
(N3RO)
1273 13 6/18/2012 9/30/2015 39.39 2.49 Infant RDS
(BPD
prevention)
Preterm infants
with RDS.
o28 wk GA;
28–30 wk GA
Surfactant Positive Airway
Pressure and Pulse
Oximetry Trial in
extremely low birth
weight infants
(SUPPORT)
1316 22 2/1/2005 5/3/2008 39 1.53 Premature birth;
BPD
prevention;
retinopathy
of prematurity
Extremely
preterm
infants
(GA, 24 wk 0
d–27 wk 6 d)
Prematurity and
Respiratory Outcomes
Program (PROP)
835 13 (6
centers)
8/1/2011 4/1/2015 43 1.49 Prematurity;
respiratory
disease
Infants admitted
to the NICU
who are o29
wk GA
Efﬁcacy and Safety of
targeting lower arterial
oxygen saturations to
reduce oxygen toxicity
1201 25 12/24/2006 8/25/2010 44 1.09 Respiratory
insufﬁciency of
prematurity
Infants with GA
of 23 wk 0 d
through 27 wk
6 d
(continued)
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Table II. (continued).
Trial Title
Actual
Accrual
(Patients)
No. of
Sites
(Centers)
Trial
Start Date
Enrollment
Period Close
Date
Enrollment
Duration
(mo)
Recruitment
Rate
(Patients/
Site/Month) Indication Study Population
and oxidative stress in
very preterm infants:
The Canadian Oxygen
Trial (COT)
A randomized trial of
standard versus higher
oxygen saturation levels
on long term growth
and development in
infants (BOOST)
358 8 9/15/1996 9/15/2000 48 0.93 Preterm infants Infants born at
o30 wk of
gestation who
remained
dependent on
supplemental
oxygen at 32
wk of
postmenstrual
age
Efﬁcacy and safety of
methylxanthines in very
low birthweight infants
(CAP)
2000 34 10/1/1999 3/1/2007 89 0.66 Apnea of
prematurity
Birth weight
500–1250 g
Efﬁcacy and safety of
inhaled budesonide in
very preterm infants at
risk for
bronchopulmonary
dysplasia (NEuroSIS)
863 40 4/1/2010 12/31/2012 33.02 0.65 BPD prevention o28 wk GA
Trial of Late Surfactant
for Prevention of
Bronchopulmonary
Dysplasia: A study in
ventilated preterm
511 25 1/1/2010 1/1/2013 36 0.56 BPD prevention o28 wk age
(continued)
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Table II. (continued).
Trial Title
Actual
Accrual
(Patients)
No. of
Sites
(Centers)
Trial
Start Date
Enrollment
Period Close
Date
Enrollment
Duration
(mo)
Recruitment
Rate
(Patients/
Site/Month) Indication Study Population
infants receiving
inhaled nitric oxide
(Surfactant Study )
(TOLSURF)
Inhaled Nitric Oxide
(INO) for the
Prevention of
Bronchopulmonary
Dysplasia (BPD) in
Preterm Infants
Requiring Mechanical
Ventilation or Positive
Pressure Support on
Days 5–15 After Birth
(NewNO)
451 33 11/1/2009 2/27/2012 27.9 0.49 Infant RDS
(BPD
prevention)
Preterm infants
with RDS.
o28 wk GA,
28–30 wk GA
Early Prevention of
bronchopulmonary
Dysplasia and
Neonatal Mortality in
Very Preterm Infants
Using Low Dose of
Hydrocortisone: A
Randomized
Controlled Trial
(PREMILOC)
523 21 5/25/2008 1/31/2014 68 0.36 BPD prevention o28 wk GA
Source: Chiesi Farmaceutici (Scientiﬁc Information Dept. - G. Mazzola).
BPD ¼ bronchopulmonary dysplasia; GA ¼ gestational age; NICU ¼ neonatal intensive care unit; RDS ¼ respiratory distress syndrome; VLBW ¼ very-low-birth-
weight.
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Clinical TherapeuticsCONCLUSIONS
Provided that the scientiﬁc, ethical, and safety aspects of
co-enrollment can be adequately addressed, there should
be no barrier to the co-enrollment of eligible neonates in
41 clinical trial. Careful consideration of the risks and
beneﬁts both to the neonate and to the research studies
must occur before any co-enrollment. Although partic-
ipation in 41 clinical trial using similar therapeutic
targets and/or primary outcome measures should be
discouraged, studies involving various conditions that
involve a different therapeutic target organ and different
primary outcome measures may be permitted following
agreements between the investigators, sponsors, and
other regulatory bodies. The regulatory agencies con-
sider adequate safety monitoring, scientiﬁc rigor and
validity, and informed, voluntary parental consent to be
paramount. In addition to facilitating more rapid enroll-
ment in much-needed neonatal clinical trials, co-enroll-
ment may allow for access to investigational agents for
conditions without approved therapies.ACKNOWLEDGMENTS
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